Skip to content

Mystical experience research: what the evidence shows

Profound states of unity and self-transcendence, and their measured role as mediators of therapeutic outcomes.

State of the evidence

Synthesized

Synthesized from 21 studies in the library · AI-generated, grounded in the abstracts below

Found by searching the library for Mystical experience, mystical-type experience, unitive experience, peak experience, noetic quality, then ranked by relevance.

The research consistently links psilocybin-occasioned mystical experiences to meaningful and lasting positive outcomes: greater personal meaning and spiritual significance, increased openness, prosocial attitude change, and reduced anxiety, depression, and substance use. Across trials and reviews, mystical experience intensity often statistically mediates these therapeutic effects, and the effect appears dose-related, with complete mystical experiences more common at higher doses. The main caveats are small samples, mostly open-label or single-site designs, limited demographic diversity, and reliance on self-report, so the mediating role is suggestive rather than firmly established.

Evidence by study

Direction is which way each study's own result points, not our rating of the study. All 25 matching studies were reviewed; the 21 that directly address the question are shown here.

What the directions mean
Supports:
the study found the intervention worked, or its hypothesis held.
Opposes:
it found the opposite, no benefit or a harm.
No effect:
no significant difference either way.
Mixed:
effects in both directions within the same study.
Unclear:
the abstract does not report a direction.
Study Design Sample size Direction Finding
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial 2016 RCT (double-blind, placebo-controlled, crossover) 29 Supports Single-dose psilocybin with psychotherapy produced rapid and enduring reductions in anxiety and depression, and the psilocybin-induced mystical experience mediated the therapeutic effect.
Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance 2006 double-blind study 36 Supports High-dose psilocybin increased measures of mystical experience and was rated at 2 months as having substantial personal and spiritual significance.
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. 2011 RCT (dose-effect, double-blind) 18 Supports At 20 and/or 30 mg/70 kg, 72% of volunteers had mystical-type experiences, which were rated as personally and spiritually significant with sustained positive changes in attitudes, mood, and behavior undiminished at 14 months.
Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness 2011 double-blind controlled study Supports High-dose psilocybin produced significant increases in Openness, and among participants who had mystical experiences Openness remained elevated more than a year later.
Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later 2008 double-blind study with 14-month follow-up 36 Supports At 14 months, 58% rated the psilocybin experience among the five most personally meaningful and 67% among the five most spiritually significant of their lives, with the session-day mystical experience measure central to these ratings.
Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin 2015 validation study (pooled laboratory data) 184 Supports The MEQ30 showed reliability and validity, and its latent scores positively predicted persisting changes in attitudes, behavior, and well-being attributed to psilocybin.
Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors 2017 RCT 75 Supports High-dose psilocybin produced enduring increases in prosocial attitudes and psychological functioning at 6 months, with mystical-type experience and practice rates as determinants of the effects.
Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. 2019 integrative review Supports Reviews evidence that classic psychedelics occasion mystical experiences and show potential as therapeutics for distress, depression, and addiction, while noting naturalistic-use associations with positive mental health outcomes.
Psilocybin-Occasioned Mystical Experiences in the Treatment of Tobacco Addiction 2015 open-label pilot study 15 Supports Abstainers at 6 months scored significantly higher on psilocybin-occasioned mystical experience than non-abstainers, with no difference in overall drug intensity, suggesting a mediating role of mystical experience.
Factor Analysis of the Mystical Experience Questionnaire: A Study of Experiences Occasioned by the Hallucinogen Psilocybin 2012 factor analysis (exploratory plus confirmatory replication) 1602 Supports The 30-item Mystical Experience Questionnaire showed a reliable four-factor structure (unity/noetic quality/sacredness, positive mood, transcendence of time/space, ineffability) that distinguished those who had a mystical experience from those who did not.
Neural correlates of a mystical experience in Carmelite nuns 2006 observational cohort (fMRI) Supports A self-reported state of union with God was associated with activation across multiple brain regions including orbitofrontal, temporal, parietal, prefrontal, cingulate, insular, caudate, and brainstem areas.
Religious and Mystical Experiences as Artifacts of Temporal Lobe Function: A General Hypothesis 1983 theoretical paper Unclear Argues that mystical and religious experiences are evoked by transient electrical microseizures in deep temporal lobe structures, often precipitated by existential crises and reducing death anxiety.
Psychedelics, Mystical Experience, and Therapeutic Efficacy: A Systematic Review 2022 systematic review Supports Ten of twelve reviewed studies found a significant association (correlation, mediation, or prediction) between mystical experience and symptom reduction across cancer-related distress, substance use disorder, and depressive disorders.
Classic Hallucinogens and Mystical Experiences: Phenomenology and Neural Correlates. 2018 review Supports Controlled double-blind studies show psilocybin occasions complete mystical experiences in the majority of participants in a dose-dependent manner, with enduring effects on mood, attitudes, and behavior and links to therapeutic outcomes.
Peak experiences and the afterglow phenomenon: When and how do therapeutic effects of hallucinogens depend on psychedelic experiences? 2015 review Mixed Concludes that pharmacological and psychological actions of psychedelics, including peak experiences and afterglow, appear to contribute differently to therapeutic effects depending on the pathology.
Mystical Experiences Mediate the Effects of Psilocybin-Assisted Psychotherapy + Mindfulness-Based Stress Reduction on Trait Mindfulness and Depression Symptoms: Mechanistic Results from a Randomized Controlled Trial 2026 RCT with mediation analysis 25 Supports Adding psilocybin-assisted therapy to MBSR improved mindfulness and savoring at 2 weeks, and exploratory mediation found significant indirect effects of mystical experience intensity on trait mindfulness and depressive symptom change.
Artificial Intelligence at the Boundary of Spiritual Experience and Psychopathology: A Scoping Review of Evidence from Türkiye, the USA, the UK, Poland, South Korea, and Israel. 2026 scoping review 9 Mixed Reports that conversational AI was described as a catalyst or amplifier of spiritually framed delusions in the presence of psychosis or impaired reality testing, while machine-learning models showed preliminary potential for detecting psychotic episodes and predicting relapse.
Mysticism: Process and Event? From Causality to Motivation in the Phenomenology of Mystical Experience According to Edith Stein 2026 theoretical/philosophical paper Unclear Argues that Edith Stein's phenomenology treats mystical experience as involving an anthropological structure in which the subject actively configures itself in response to divine initiative, rather than as a linear culmination of spiritual development.
Hypnosis-based intervention for mystical experiences: a qualitative analysis. 2026 qualitative study Supports Participants described personally significant hypnotically induced experiences with intense emotion, hallucination-like phenomena, and insight resembling psychedelic mystical experiences, including elements not captured by existing instruments.
Development of Japanese Versions of the 4‐Item Mystical Experience Questionnaire and 7‐Item Challenging Experience Questionnaire 2026 questionnaire translation and cultural adaptation study Unclear Developed authorized Japanese versions of the MEQ-4 and CEQ-7 for assessing mystical and challenging experiences, with future validation still needed.
The occurrence and potential role of mystical experiences in MDMA-assisted therapy for PTSD: A secondary analysis 2026 secondary analysis of two phase 2 RCTs 53 Mixed MDMA sessions produced significantly higher MEQ30 scores than active placebo, and only the Positive Mood subscale significantly mediated PTSD symptom reduction while total and other subscale effects were non-significant.

Points of agreement

  • Psilocybin reliably occasions mystical-type experiences under supportive, controlled conditions, with effects increasing at higher doses.
  • Mystical experience intensity is repeatedly associated with, and often statistically mediates, persisting positive changes in mood, attitudes, behavior, and well-being.
  • Therapeutic benefits in anxiety, depression, and substance use are linked to mystical experience rather than to overall drug intensity.
  • Validated instruments (MEQ30 and its factor structure) consistently capture mystical experience and predict outcomes.
  • Benefits are reported as durable, extending from months to over a year in several studies.

Conflicts

  • In MDMA-assisted therapy for PTSD, only the Positive Mood subscale mediated symptom reduction, whereas psilocybin studies emphasize total mystical experience scores.
  • One review concludes that pharmacological and psychological mechanisms contribute differently depending on the pathology, tempering a single-mechanism account.
  • Theoretical accounts differ on the origin of mystical experience, from temporal-lobe microseizures to phenomenological and theological framings.

Gaps

  • Small sample sizes and limited demographic diversity across most trials.
  • Many studies are open-label or lack adequate blinding, leaving expectancy and bias concerns.
  • Durability beyond roughly 14 months is largely unexamined.
  • Dose-response relationships and predictors of mystical experience intensity are incompletely characterized.
  • Causal mediation is inferred from correlational and exploratory analyses rather than confirmed experimentally.
  • Non-psilocybin contexts (hypnosis, MDMA, naturalistic religious experience) are studied far less and with weaker designs.
Browse these studies in the library

Common questions

What does the research agree on about mystical experience?
  • Psilocybin reliably occasions mystical-type experiences under supportive, controlled conditions, with effects increasing at higher doses.
  • Mystical experience intensity is repeatedly associated with, and often statistically mediates, persisting positive changes in mood, attitudes, behavior, and well-being.
  • Therapeutic benefits in anxiety, depression, and substance use are linked to mystical experience rather than to overall drug intensity.
  • Validated instruments (MEQ30 and its factor structure) consistently capture mystical experience and predict outcomes.
  • Benefits are reported as durable, extending from months to over a year in several studies.
Where do studies on mystical experience conflict?
  • In MDMA-assisted therapy for PTSD, only the Positive Mood subscale mediated symptom reduction, whereas psilocybin studies emphasize total mystical experience scores.
  • One review concludes that pharmacological and psychological mechanisms contribute differently depending on the pathology, tempering a single-mechanism account.
  • Theoretical accounts differ on the origin of mystical experience, from temporal-lobe microseizures to phenomenological and theological framings.
What is still unknown about mystical experience?
  • Small sample sizes and limited demographic diversity across most trials.
  • Many studies are open-label or lack adequate blinding, leaving expectancy and bias concerns.
  • Durability beyond roughly 14 months is largely unexamined.
  • Dose-response relationships and predictors of mystical experience intensity are incompletely characterized.
  • Causal mediation is inferred from correlational and exploratory analyses rather than confirmed experimentally.
  • Non-psilocybin contexts (hypnosis, MDMA, naturalistic religious experience) are studied far less and with weaker designs.
How we analyze this

This synthesis reads the 15 most-cited and 10 most recent studies whose primary subject is Mystical experience, up to 25 in all. The most-cited set anchors the established evidence, and the recent set surfaces work that is too new to have gathered citations yet.

A study qualifies only when Mystical experience or a known alias appears in its title or keywords, so broad reviews that mention it only in passing are left out. Each study is read from its abstract, strongest evidence first, and the summary reports the direction of the results along with any conflicts and gaps.

The full method, including what a person does and does not review, is on the methods page.

Ask your own question in the Research Synthesis Tool

Latest monthly recap: July 2026 →

3,344 articles · 972 from the last two years · 1,294,590 participants across 881 studies reporting sample size

Common study designs

review 193 qualitative study 145 historical analysis 173 cross-sectional survey 100 theoretical or philosophical paper 1506

Research volume by year

Compare topics →

411 studies whose primary subject is mystical experience since 2002

Studies about mystical experience per year, 2002 to 2026, peaking at 52 in 2025 Bar chart: one bar per year, taller where more studies were published that year. 0 30 60 2005 2010 2015 2020 2025
2026 is partial
Show the numbers
Studies about mystical experience per year, 2002 to 2026, peaking at 52 in 2025
Year Studies
2002 1
2003 5
2004 4
2005 4
2006 5
2007 6
2008 3
2009 6
2010 2
2011 8
2012 7
2013 7
2014 9
2015 16
2016 10
2017 10
2018 14
2019 13
2020 24
2021 29
2022 40
2023 41
2024 43
2025 52
2026 52

Research

Synthesize the evidence → Search all →

Peak experiences in educational practice and the formation of professional identity among early childhood teachers

European Early Childhood Education Research Journal October 21, 2026 Ivan Lukšík

This study explores how early childhood teachers interpret extraordinary educational experiences (peak experiences) and the meanings they attribute to these experiences in the process of shaping their professional identity. The research employed a mixed-method design consisting of a descriptive quantitative analysis of the occurrence of peak experiences (N = 159) and a reflexive thematic...

DOI: 10.1080/1350293x.2026.2743081 (opens in new tab)

Dance Psychology: Movement as Mind — Chapter 3: Flow Peak Experience And The Dancing State

Zenodo (CERN European Organization for Nuclear Research) October 8, 2026 Ammanuel Santa Anna preprint

Chapter from Dance Psychology: Movement as Mind by Santa Anna, Ammanuel, published under The Luminous Library (Luminous Prosperity Inc.). Released as part of Operation Free Books For All — offered openly to establish and connect the field of dance psychology to its adjacent academic literatures.

DOI: 10.5281/zenodo.23246166 (opens in new tab)

Mystical Experiences Mediate the Effects of Psilocybin-Assisted Psychotherapy + Mindfulness-Based Stress Reduction on Trait Mindfulness and Depression Symptoms: Mechanistic Results from a Randomized Controlled Trial

Journal of Affective Disorders Reports October 1, 2026 Kevin Byrne, Madeleine Odette, Eric L Garland et al.

ABSTRACT Background Healthcare workers experienced amplified depression and burnout during COVID-19. Both Mindfulness Based Stress Reduction (MBSR) and psilocybin have been shown to reduce depressive symptoms in this population, however the psychological mechanisms by which adding psilocybin to mindfulness training improves depression and trait mindfulness remain incompletely characterized....

DOI: 10.1016/j.jadr.2026.101187 (opens in new tab)

Mysticism: Process and Event? From Causality to Motivation in the Phenomenology of Mystical Experience According to Edith Stein

Religions September 10, 2026 Gwendolyn Araya Gómez

(1) Background: This article situates Edith Stein within the 20th-century debate on the nature of mystical experience, framing it as a philosophical problem concerning the relationship between divine initiative and human freedom, and aims to reassess dominant developmental interpretations of mysticism. It argues that, alongside theological models such as that of Réginald Garrigou-Lagrange,...

DOI: 10.3390/rel17091055 (opens in new tab)

Hypnosis-based intervention for mystical experiences: a qualitative analysis.

American Journal of Clinical Hypnosis September 4, 2026 Chris E. Corlett, Jesse J. Norris, Sharika Majeti et al.

Mystical experiences or peak spiritual experiences have been shown to be of potential benefit in facilitating personal growth and ameliorating anxiety and depression. A pilot study demonstrated the feasibility of hypnotically induced mystical experiences. Althrough participants' qualitative experiences were recorded and analyzed, they have yet to be reported. Although participants' qualitative...

DOI: 10.1080/00029157.2026.2704105 (opens in new tab) Full text (opens in new tab) Mystical experience Anomalous phenomena Hypnosis Intense emotional responses +2

Development of Japanese Versions of the 4‐Item Mystical Experience Questionnaire and 7‐Item Challenging Experience Questionnaire

Neuropsychopharmacology Reports August 27, 2026 Futaba Umemura, Hiroko Kotajima‐Murakami, Justin C Strickland et al.

INTRODUCTION: Interest in therapeutic applications of psychedelics has recently resurged. Mystical-type and challenging experiences that are elicited by psychedelics are commonly assessed using the 30-item Mystical Experience Questionnaire (MEQ-30) and the 26-item Challenging Experience Questionnaire (CEQ), respectively. The brief 4-item MEQ (MEQ-4) and 7-item CEQ (CEQ-7) may reduce respondent...

DOI: 10.1002/npr2.70164 (opens in new tab)

The occurrence and potential role of mystical experiences in MDMA-assisted therapy for PTSD: A secondary analysis

Journal of Psychopharmacology August 6, 2026 Tijmen Bostoen, Erwin Krediet, Annette van Schagen et al.

Background: The potential safety and efficacy of the psychedelic 3,4-methylenedioxymethamphetamine-assisted therapy (MDMA-AT) for post-traumatic stress disorder (PTSD) has been researched in phase 2 and phase 3 clinical trials. We examined the occurrence and role of mystical experiences in MDMA-AT. Methods: Data were sourced from two phase 2 randomized trials of MDMA-AT for chronic PTSD, in...

DOI: 10.1177/02698811261464502 (opens in new tab)

Dialogues in the dark: Reconceptualizing peak experience in night tourism through autoethnography

Tourist Studies August 4, 2026 Tran Thi Tuyen

Night tourism is commonly examined through economic activity and entertainment consumption, while its emotional and introspective dimensions remain underexplored. This study investigates how nocturnal environments shape inner immersion and emotional processes that lead to peak experiences. Using analytic autoethnography, the research draws on reflective field notes and experiential observations...

DOI: 10.1177/14687976261474314 (opens in new tab)

Christian Counseling Understanding and Critique of Maslow's Hierarchy of Needs Theory - Centering around Peak Experiences & Experiences of the Holy Spirit -

Theology and praxis July 30, 2026 Joseph Jeon

This study examines Abraham Maslow’s hierarchy of needs and the concept of peak experience from the perspective of Christian counseling, focusing on his explanation of human motivation through a hierarchy of needs and its later expansion to include cognitive, aesthetic, and self-transcendence needs. Maslow’s theory provides valuable insights into understanding human beings as holistic persons...

DOI: 10.14387/jkspth.2026.100.119 (opens in new tab)

Mystical Experience: The Core of Spirituality and Religion A Panikkarian View

Zenodo (CERN European Organization for Nuclear Research) July 29, 2026 Varghese Manimala preprint

Any person aspiring to become a mystic cannot cut oneself off from the banalities of life and pretend to be travelling in a world toto caelo different from this experiential world. Such mysticism cannot be effective nor can it invite others because it will appear to be too ethereal. Hence the challenge for any mystic is to make the real life come into the purview of the mystical dimension and...

DOI: 10.5281/zenodo.21672042 (opens in new tab)

Clinical trials

All Mystical experience trials →